COMMUNIQUÉS West-GlobeNewswire
-
Pioneering screening test offers potential to find more aggressive prostate cancers
22/06/2026 -
MoonLake Immunotherapeutics Announces Proposed Public Offering
22/06/2026 -
uniQure Announces $150 Million Proposed Public Offering
22/06/2026 -
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
22/06/2026 -
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
22/06/2026 -
Flyte Partners with GSE Worldwide and PGA TOUR Professional Emiliano Grillo, Debuted at the 2026 U.S. Open
22/06/2026 -
Transactions of Managers and Closely Associated Persons
23/06/2026 -
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
22/06/2026 -
NADP and AADOM announce partnership
22/06/2026 -
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
22/06/2026 -
iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
22/06/2026 -
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2026
22/06/2026 -
Genista Launches Refreshed Brand and Website, Positioning Itself as the Operating System for Product Safety
22/06/2026 -
Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit
22/06/2026 -
Ozari Health Releases 2026 Online GLP-1 Provider Checklist
22/06/2026 -
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026
22/06/2026 -
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
22/06/2026 -
TETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic Stroke
22/06/2026 -
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026
Pages